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Magnetic resonance (MR) methods to detect and quantify fluorine (19F) nuclei provide the opportunity to
study the fate of cellular transplants in vivo. Cells are typically labeledwith 19F nanoparticles, introduced into
living organisms and tracked by 19F MR methods. Background-free imaging and quantification of cell
numbers are amongst the strengths of 19F MR-based cell tracking but challenges pertaining to signal
sensitivity and cell detection exist. In this study we aimed to overcome these limitations bymanipulating the
aminophospholipid composition of 19F nanoparticles in order to promote their uptake by dendritic cells
(DCs). As critical components of biological membranes, phosphatidylethanolamines (PE) were studied.
Both microscopy and MR spectroscopy methods revealed a striking (at least one order of magnitude)
increase in cytoplasmic uptake of 19F nanoparticles in DCs following enrichment with
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE). The impact of enriching 19F nanoparticles
with PE on DC migration was also investigated. By manipulating the nanoparticle composition and as a
result the cellular uptakewe provide here oneway of boosting 19F signal per cell in order to overcome some of
the limitations related to 19F MR signal sensitivity. The boost in signal is ultimately necessary to detect and
track cells in vivo.
T
racking immune cells in vivo is a prerequisite for understanding the development of pathologies associated
with disorders of the immune system1. Dendritic cells (DCs) are immune cells that play key roles in the
development of immunity and immunopathology. Of note, an understanding of the distribution and fate of
cells such as DCs following their therapeutic application in vivo such as in cancers is crucial to assess treatment
efficacy2. The lack of a priori knowledge of the kinetics and dynamics of these cells during physiological and
pathological settings makes their localization a challenging task. It is therefore a top priority to develop methods
for the non-invasive spatiotemporal tracking of immune cells in vivo that can be easily transferred to the clinical
scenario3–6.
Magnetic resonance imaging (MRI) offers an ideal solution for tracking cells in vivo due to its non-invasiveness
and clinical translation as well as the opportunity of repetitive measurements and longitudinal studies. Major
challenges in differentiating cells from the recipient tissue and signal sensitivity constraints nevertheless exist. For
instance, iron oxide nanoparticles that reduce T2* relaxation7 inMRhave been used to label cells, however present
a challengewhereby the contrast created by the labeled cells is not easily distinguishable from other intrinsic tissue
contrasts8. This limitation of cellular MRI is surmounted by fluorine (19F) MR techniques3. Carbon-bound
fluorine is absent in living organisms. This guarantees background-free MR signals for externally-applied 19F
compounds. Therefore 19F MR techniques are advantageous for localizing 19F-containing exogenous agents in
vivo since they permit complete signal selectivity and specificity9–11. Importantly, the 19F MR signal can also be
equated tomeasurable cell numbers within defined regions6,12. For in vivo tracking, cells are typically labeled with
nanoparticles enriched with perfluorocompounds (PFCs) prior to their introduction into living organisms3–6.
These compounds possess unique properties (inertness, biocompatibility and hydrophobicity) which stem from
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the C–F bonds within the molecular structure13. Hydrophobicity
becomes more significant with increasing number of 19F atoms and
a critical factor for increasing the ability of these compounds to cross
biological membranes14,15. Making use of these properties, 19F-rich
nanoparticles are prepared via various techniques – commonly by
emulsifying PFCs with phospholipids or surfactants – in order to
label and track immune cells in vivo with the aid of combined 19F
and anatomical/proton (1H) MR imaging as well as 19F spectro-
scopy techniques3–6. Notwithstanding the benefits specified above,
some limitations and challenges exist for 19F-based MR techniques,
especially those pertaining to detection limit and signal sensitivity.
These limitations come at a cost in increased signal averaging and
thus acquisition times to compensate for low signal-to-noise ratio
(SNR). There is a need to optimize cellular 19F MR methods espe-
cially since clinical trials with DC vaccines have thus far provided a
proof-of-principle as cancer therapy16 and the applicability of 19F
MR techniques for DC vaccines are being explored in colorectal
cancer patients17.
In the present study we explored the possibility of altering the
composition of 19F nanoparticles in order to maximize their uptake
by DCs and therefore to promote the 19F signal per cell. To meet this
goal, we investigated the incorporation of phosphatidylethanola-
mines (PEs) into the 19F nanoparticle shell. PEs are aminophospho-
lipids that constitute an integral part of biological membranes18,19.
These aminophospholipids are cone-shaped, they do not form
bilayers but inverted hexagonal phases, are believed to exert a lateral
pressure that regulates membrane curvature and, are thought to
stabilize membrane proteins in their optimum conformations20. PE
analogs have been used successfully in non-viral transfection sys-
tems21,22 as well as in nanotube carriers for drug delivery23. For all
these reasons we studied the influence of PE enrichment on the
uptake of 19F nanoparticle by DCs. Using both electron microscopy
and 19F MR spectroscopy we observed a dramatic increase in uptake
of 19F nanoparticles enriched with 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (DPPE) by DCs. As a result, the 19F signal/
cell was increased by at least one order of magnitude and the cell
detection limit considerably reduced.With this advantage at handwe
could reduce the PFCE concentration per nanoparticle to avoid
impairment in cell function, particularly cell migration. Our findings
further offset the constraints of 19F MR and bring us a step closer to
the crucial goal of ultimate signal sensitivity and minimal cell detec-
tion limit.
Results
Dipalmitoyl-Phosphoethanolamine promotes nanoparticle uptake
by DCs. Considering the power of PE analogs to promote cellular
uptake in transfection and drug delivery systems21–23, we first set off to
enrich 19F-rich (PFCE) nanoparticles (NP) used in our previous
studies5,6,12 with different phospholipids of the phosphoethanola-
mine (PE) family (Figure 1A). The basic nanoparticles were
prepared using Pluronic F-68 block copolymer. To enrich the 19F
nanoparticles with PE we chose two analogs differing in their two
long fatty acid hydrocarbon chains; one PE contained one
unsaturated bond (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethan-
olamine, POPE) and the other PE consisted of only saturated bonds
(1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, DPPE). Also
consisting solely of saturated bonds was the third candidate we
chose: 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE),
bound to polyethylene glycol-2000 (DSPE-PEG2000). PEG is
widely employed as polymeric steric stabilizer and is anchored to
stealth liposomal surfaces via cross-linked DSPE lipid24,25. PEG2000
was chosen since blocks of higher molecular weight in similarly-sized
nanoparticles have been shown to reduce nanoparticle uptake in
macrophages (uptake: PEG2000 . PEG5000 . PEG10000)26. We
used DPPE and POPE to enrich Pluronic-based PFCE-containing
nanoemulsions and prepared liposomal PFCE nanoparticles using
DSPE-PEG2000. For all nanoparticle preparations, the molar
fraction of the constituents and the physical characteristics (size,
polydispersity, surface charge) are shown in Table 1.
To determine differences in uptake between the different nano-
particle groups we performed 19F magnetic resonance spectroscopy
(MRS) of the fixed DCs following labeling to determine the amount
of 19F compound (PFCE) per 106 cells. Pluronic-nanoparticles
enriched with PE polymers appeared to be taken up more efficiently
by DCs than basic Pluronic nanoparticles and DSPE–PEG2000 lipo-
somes as determined by the increase in cellular 19F signal. POPE
enrichment already resulted in an increased 19F signal (POPE 1x:
138 nmol per 106 cells and POPE 10x: 179 nmol per 106 cells) com-
pared to the basic nanoparticle formulations (74 nmol per 106 cells)
and DSPE–PEG2000 liposomes (69 nmol per 106 cells). When we
employed DPPE to enrich the nanoparticle shell, we observed an
even stronger enhancement of 19F signal (771 nmol per 106 cells)
(Figure 1B). This equates to an increase in 19F spins from 0.89 3
1012 19F spins (in basic formulations) to 0.93 3 1013 19F spins (in
DPPE-enriched nanoparticles) per dendritic cell unit.
Figure 1 | Selection of phosphoethanolamines for enrichment of PFCE nanoparticles. (a) Chemical structures of DPPE (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine), POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine used for the 19F nanoemulsion and DSPE-PEG2000 (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol) -2000]) used for the liposomal nanoparticles. (b)DCs were labeledwith
different 19F nanoparticle preparations (DSPE-PEG2000, Pluronic-basic, Pluronic-POPE and Pluronic-DPPE) using a PFCE concentration of 20 mmol
per 107, fixed in 2% PFA and transferred (106) to NMR tubes. After positioning in a 19F-tuned loop coil (seeMethods), 19F signal was acquired using a 90u
block excitation pulse with 10 kHz bandwidth and the PFCE amount per 106 calculated using a 500 mM PFCE standard.
www.nature.com/scientificreports
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Intracellular appearance of Dipalmitoyl-Phosphoethanolamine-
enriched nanoparticles. Despite the dramatic differences in 19F
signal within DCs between the different nanoparticles, we did not
observe any conspicuous differences in the shape of the nanoparticles
employed as investigated by Cryo-TEM (Figure 2A). We next went
on to investigate whether the striking increase in 19F signal in the
DPPE-enriched nanoparticles was the result of increased nano-
particle uptake. In ultrathin sections of DCs derived from the same
culture conditions, we observed intense differences in cytoplasmic
uptake between the nanoparticle formulations (Figure 2B, EM
images in upper two panels and lower left panel). We commonly
observed the nanoparticles as white globules within the cell cyto-
plasm but similar to our previous observations5 the nanoparticles
also often appeared compartmentalized as clusters in a lipid
membrane capsule within an amorphous grey compartment. We
also observed increased DC uptake of nanoparticles enriched with
DPPE linked to the tracer dye Rhodamine as shown from the
Rhodamine fluorescence imaged by laser scanning microscopy
Table 1 | Composition and characteristics of nanoparticles (NP) used
Nanoparticle
Molar fraction of constituents Physical characteristics
Pluronic PE Lipid PFCE Particle size Polydispersity Zeta Potential
X X X [nm] (6S.D.) Index (6S.D.) [mV] (6S.D.)
Pluronic-Basic—PFCE NP 0.01419 — 0.98581 186 (15) 0.06 (0.02) 24.81 (1.52)
Pluronic-(DPPE)—PFCE NP 0.00582 0.00001 0.99417 246 (16) 0.30 (0.02) 218.55 (1.61)
Pluronic-(POPE 1x)—PFCE NP 0.00580 0.00001 0.99418 200 (6) 0.03 (0.01) 212.13 (0.31)
Pluronic-(POPE 10x)—PFCE NP 0.00580 0.00011 0.99408 200 (1) 0.12 (0.08) 27.37 (0.53)
(DSPE-PEG2000)—PFCE NP — 0.00006 0.99994 216 (19) 0.20 (0.01) 228.43 (1.33)
Dynamic light scattering was used to measure Z-average diameter (mean diameter based on intensity of scattered light and sensitive to presence of large particles), peak diameter, peak width and
polydispersity index (PdI). PFCE 5 perfluoro-15-crown-5-ether; X5 mole fraction; PE 5 phosphoethanolamine;DPPE5 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; POPE5 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine; DSPE-PEG2000 5 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethylene glycol)-2000.
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Figure 2 | Appearance of phosphoethanolamine-enriched PFCE nanoparticles. (a) Cryogenic transmission electron microscopy (TEM) images of
DSPE-PEG2000, Pluronic-basic, Pluronic-DPPE and Pluronic-DPPE-Rhodamine nanoparticles encapsulating PFCE fluorine compound (size-bar for
TEM images: 50 nm). (b) Upper two panels and lower left panel show ultrathin sections of DCs labeled with DSPE-PEG2000, basic and DPPE-enriched
PFCE nanoparticles (size-bar for EM images: 2 mm). Lower right panel shows a laser scanningmicroscopy image of DCs labeled with DPPE-Rhodamine-
enriched 19F nanoparticles (size-bar for LSM image: 10 mm). (c) DCs were labeled with different nanoparticle preparations (DSPE-PEG2000 NP, basic
NP, DPPE-NP and DPPE-Rhodamine-NP) using a PFCE concentration of 10 mmol per 107, fixed in 2% PFA and transferred (106) to NMR tubes. 19F
signal was acquired using a 90u block excitation pulse and the PFCE amount per 106 calculated using a 500 mM PFCE standard.
www.nature.com/scientificreports
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(Figure 2B, LSM image in lower right panel); these nanoparticles were
also loaded into DCs similarly to the non-Rhodamine linked DPPE-
enriched 19F nanoparticles.
As a next step, the same groups of cells labeledwith basic (-), DPPE
or DPPE-Rhodamine 19F nanoparticles as well as DSPE-PEG2000
liposomes were investigated by 19F MRS (Figure 2C). Similarly to the
results in Figure 1B, we observed a significant increase in 19F signal
per cell when DCs were labeled with nanoparticles enriched with
DPPE (361 nmol per 106 cells ; 0.44 3 1013 19F spins per cell)
compared to the basic formulation (25 nmol per 106 cells ; 0.3 3
1012 19F spins per cell) and DSPE–PEG2000 liposomes (35 nmol per
106 cells; 0.42 3 1012 19F spins per cell) (Figure 2C). The 19F signal
per cell in DCs labeled with DPPE-Rhodamine nanoparticles was
slightly lower (264 nmol per 106 cells ; 0.32 3 1013 19F spins per
cell) than those from DCs labeled with nanoparticles enriched with
DPPE containing no Rhodamine (Figure 2C).
Titrating the 19F label in DPPE-enriched nanoparticles. In the next
experiments we performed dose titration curves for the 19F label
(perfluoro-15-crown-5-ether, PFCE) in cells loaded with DPPE or
basic 19F nanoparticles. With these experiments we wanted to
determine the lowest concentration of PFCE feasible for detecting
a sufficient 19F signal in MRS (Figure 3). Using the Pluronic-based
nanoparticles we had previously employed up to 40 mmol PFCE per
107 DCs in culture5. Taking into account the dramatic increase in 19F
signal achieved following enrichment with DPPE we titrated the
PFCE amount from 40 mmol to 2 mmol PFCE per 107 DCs. In line
with the previous results (Figure 1–2), 5 mmol PFCE label within
DPPE 19F nanoparticles gave a larger 19F signal than 40 mmol
PFCE label within basic 19F nanoparticles when used to label 107
DCs (Figure 3A, 3B). This observation can be made already from
the spectral representations of the 19F signal (Figure 3A) and upon
quantification of the 19F signal from the maximum signal intensity of
the FID (Figure 3B). By extrapolating the linear fit ([PFCE]label/
[PFCE]intracellular) for the basic 19F nanoparticles, we estimate a
requirement of 70 mmol for the basic 19F nanoparticles to reach the
equivalent 19F signal of DCs labeled with 5 mmol DPPE-enriched
nanoparticles (D PFCE concentration ,65 mmol) (Figure 3B).
Higher concentrations of 19F label hinder DC migration.
Ultimately, the 19F-labeled DCs will be applied in living organisms.
Therefore it was necessary to determine the influence of increasing
PFCE labeling on DC migration for both DPPE-enriched as well as
basic 19F nanoparticles. For this, we employed an agarose assay to
determine the chemotaxis of DCs towards a chemokine gradient
following maturation with bacterial lipopolysaccharide (LPS). In
the initial experiments comparing 19F signal between basic and
DPPE nanoparticles we employed 10–20 mmol of PFCE to label
107 cells (Figure 1–2). When we investigated the influence of
10 mmol PFCE label on DC migration, we observed differences in
the number of DCs moving towards chemokine between unlabeled
cells treated for 18 hwith LPS and cells labeled with 19F nanoparticles
(Figure 4A). For DCs labeled withDPPE 19F nanoparticles, quantities
of PFCE higher than 10 mmol per 107 cells reduced the migration of
DCs towards chemokine by more than 50% (Figure 4B). For lower
doses of PFCE – specifically 5 mmol per 107 cells – the reduction in
migration was less extensive and the difference between DPPE and
basic 19F nanoparticles less substantial; the inhibition in migration
for DPPE-NP labeled cells was 35% (n 5 1270) and the inhibition in
migration for basic-NP labeled DCs was 22% (n 5 1555) in
comparison to unlabeled DCs (n 5 1985) (Figure 4B). This finding
and considering our previous observation that 5 mmol PFCE in
DPPE nanoparticles generate an equivalent 19F signal by at least
one order more PFCE in basic nanoparticles (Figure 3B), led us to
employ 5 mmol PFCE for all the following experiments.
Lower number of cells detected following labeling with DPPE-
enriched nanoparticles. Using 5 mmol PFCE for both DPPE and
basic 19F nanoparticles we next measured the intracellular 19F signal
in increasing numbers of DCs to determine the cell detection limit.
We measured the 19F signal in each fixed cell sample by performing
global spectroscopy of the NMR tube containing the cell pellet (see
Methods). By using a 19F standard (500 mM PFCE) we quantified the
amount of PFCE within each sample. Both spectral representation of
the 19F signal (Figure 5A) as well as PFCE quantification (Figure 5B)
for both DPPE-enriched and basic 19F nanoparticles demonstrated
that 19F signal amplitude correlates with the number of labeled cells.
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From the spectral representation of the cell dilution curves it was
already evident that far less DPPE-NP labeled DCs could be detected
than basic-NP labeled DCs (Figure 5A). It should be noted that in
these experiments (in line with the chemotaxis assays above) we used
low PFCE labeling doses (5 mmol per 107 cells) in contrast to prev-
iously published work where we commonly employed 20 mmol per
107 cells5,6,12. In the present experiments we observed that a min-
imum of 106 DCs labeled with basic nanoparticles (5 mmol) were
required to achieve a detectable 19F signal. However for DPPE-NP
labeled DCs, 1.5 3 105 of cells could be detected (Figure 5A).
Following quantification of the 19F signal from the FID fit and cal-
culation of the intracellular PFCE amount (using PFCE standard),
we observed that 105 DPPE-NP labeled DCs give a similar 19F signal
and contain similar PFCE amounts (14.48 nmol) as 106 basic-NP
labeled DCs (10.45 nmol). It can also be deduced from the spectral
representations (Figure 5A) that a baseline intracellular value of
approximately 10 nmol PFCE (Figure 5B) is the threshold above
which DCs become detectable.
Gain in sensitivity and cellular detection following labeling with
DPPE 19F nanoparticles. In order to reach the goal of this study (to
identify the influence of PE nanoparticle enrichment on signal
sensitivity in vivo), we next wanted to identify the 19F signal and
detection limit within defined regions of interest. For this we
selected DC numbers used in the cell dilution curves and
performed combined 19F/1H MRI (Figure 6A) as well as voxel-
based 19F PRESS in order to quantify the 19F signal within this
defined region (Figure 6B). We used the same radio frequency
volume coil used for tracking DCs in mice, in order to be able to
project our findings to the in vivo experiment. For the volume used to
embed cells in agarose (100 ml) within NMR tubes it was sufficient to
place a (5 3 5 3 5) mm3 PRESS voxel that covered the entire sample
(Figure 6B). The 19F/1HMR imaging experiments showed that 2.5 3
106 was the minimum amount of cells detected in the case of basic-
NP labeled DCs and 0.3 3 106 was the minimum for the DPPE-NP
labeled DCs (Figure 6A). This corresponds to a cell detection limit of
1.7 3 106 DCs per mm3 for basic-NP labeled DCs and 2 3 105 DCs
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per mm3 for DPPE-NP labeled DCs for an 19F MR scan time of
16.85 minutes (NEX 5 64). The voxel-based spectroscopy method
was more sensitive in detecting 19F signal: 0.5 3 106 basic-NP labeled
DCs and 0.15 3 106 DPPE-NP labeled DCs could be detected with
this method (Figure 6B). This corresponds to a cell detection limit of
4 3 103 DCs per mm3 for basic-NP labeled DCs and 1.2 3 103 DCs
per mm3 for DPPE-NP labeled DCs for an 19F MR scan time of
13 minutes (NEX 5 512).
To study the signal and migration efficiency of DPPE-NP labeled
DCs in vivo, we next applied DCs (107) to the left hind limbs of
C57BL/6 mice and compared their 19F signal to those labeled with
basic 19F nanoparticles (right hind limb). Three hours following
intradermal application we placed a (3 3 3 3 3) mm3 PRESS voxel
around both left and right popliteal lymph node and measured the
19F signal within each lymph node using PRESS sequence as
described above. Both from the 19F/1H MR imaging as well as from
the voxel-based spectra illustrating the region-specific 19F signal we
observed that DPPE-NP labeled DCs gave a more prominent signal
in vivo than the basic-NP labeled DCs (Figure 6C). Using the cell
calibration curves described above (Figure 5B) and the FID values at t
5 0 for the PRESS spectra, we could translate the quantified 19F signal
to the number of cells within the specific lymph node regions: we
calculated that after 3 hours 2.85 3 106 DPPE-NP labeled DCs were
present in the left lymph node and 0.79 3 105 basic-NP labeled DCs
in the right lymph nodes (Figure 6C).
Discussion
Phosphatidylethanolamines (PEs) are aminophospholipids that con-
stitute an integral part of biological membranes. However, PE ana-
logs have also been employed as components of non-biological
systems such as non-viral transfection agents21,22 and as coatings of
poorly soluble carbon nanotubes to promote cellular uptake23. In the
cell, PEs aremainly found in the inner leaflet of the lipid bilayer27 and
make up over one fourth of the whole membrane28. PEs play a role in
membrane fusion and in cell division29. These phospholipids are
translocated to intracellular surfaces via ATP-dependent mechan-
isms to maintain asymmetrical distribution within the membrane
leaflet30,31. Aminophospholipid asymmetry is necessary for preserv-
ing the viability of the cell18. The phospholipids PE, PC (phosphati-
dylcholine), PS (phosphatidylserine), PI (phosphatidylinositol) and
SM (sphingomyelin) are irregularly distributed throughout the cel-
lular membrane (2354351259 of PC5PE5PS5PI/SM) in dendritic
cells32. The variable distribution of phospholipids is necessary for
endocytosis in DCs33,34.
In this studywe investigated the influence of two PE analogs on the
uptake of fluorine-rich nanoparticles into DCs. We made use of 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) and 1-pal-
mitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) to
enrich basic nanoparticles with PE. These PEs possess different phase
transition temperatures (POPE: 125uC35; DPPE: 164uC36) and their
assemblies have very different fluidity. One important difference
between the two analogs is the presence of an unsaturated bond
within one of the fatty acid hydrocarbon chains in POPE; both fatty
acid chains in DPPE are made up of only saturated bonds
(Figure 1A).
We found that anchoring DPPE to nanoparticle structures dra-
matically improved their uptake by DCs (Figures 1–3, Figures 5–6).
We also observed an increase in cellular uptake when incorporating
POPE into the nanoparticle structure; however the increased uptake
was not as remarkable when compared to DPPE (Figure 1B). DSPE-
PEG2000 was without any effect (Figures 1–2). In our study we chose
PEG2000, with an intermediate molecular weight, in order to stabil-
izeDSPE-based nanoparticles and secure their uptake byDCs. Larger
PEG chains are associated with reduced phagocytosis: PEG2000
nanoparticles are taken up more efficiently by macrophages than
PEG4000, PEG5000 and PEG10000 coated nanoparticles26,37.
Earlier studies reported that covering nanoparticles with higher
MWPEG (e.g. PEG5000) prolongs their circulation time in vivo38–40,
probably due to the decreased phagocytosis and thereby protection
from the reticuloendothelial system26,37. In addition to cell uptake
and circulation time, the length of the PEG block influences other
biological aspects such as target recognition and uptake of delivery
systemsmediated by address molecules. While long PEG chains may
cover the vectors, short PEG chains do not inhibit their enzymatic
degradation41. Phospholipid-based drug delivery systems modified
with PEG2000 are highly efficient and specific at drug targeting in
tumor tissue, and remain longer in tumor tissue compared to other
DSPE-based carriers with other PEGmasses42–44.Molecular targeting
and cellular uptake can be further enhanced by modification with
vector molecules such as receptor-recognizing and cell-penetrating
peptides45,46. In our study we did not modify the DSPE-PEG and do
not observe any changes in uptake by DCs. Our finding correlates
with transfection studies that showed that increasing number of
methyl or methylene groups are progressively less active in transfec-
tion47. Furthermore, PEG-lipids were found to impair transfection
efficacy22. In future it will be interesting to study the impact of pep-
tide-modified DSPE-PEG nanoparticles to promote cellular uptake
in DCs46,48.
The observation that DPPE is superior to POPE with regard to
cellular uptake is however surprising since liposomal transfection
formulations doped with PE analogs revealed that analogs with
increasing acyl chain saturation were progressively less active than
unsaturated analogs47. In our study we enriched nanoparticles gen-
erated from emulsification of PFCE with Pluronic with DPPE. Since
PE is strictly bound to the cytosolic leaflet, the observed increased
efficiency of internalization of DPPE-enriched nanoparticles by DCs
could be explained by an active process translocating PE to the inner
membrane surface. It has been shown that multiple unsaturation of
the fatty acyl chain significantly decreases the interaction with cho-
lesterol in both bilayers and monolayers19. The success of conveying
nanocomplexes into the intracellular compartment is dependent on
several factors: hydrophobic alkyl side chains, saturation of C-C
bonds in hydrophobic moieties, the head group of the phospholipids
utilized to make up the nanocarrier. In a study comparing the com-
bination of a number of phospholipids to liposomal nanoparticles
used for gene delivery, combinations containing DPPE and DOPE
(1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) were most effec-
tive with regards to cellular transfection49.
PE and PS aminophospholipids are present in cell-derived mem-
brane vesicles: microparticles, microvesicles, exosomes50. Recently a
study reported that PE is extensively found on the external surface of
microparticles derived from various human cellular sources51.
Although cell-derived membrane vesicles were first discovered as a
product of platelets during blood coagulation52 and thought to be
cellular waste, it is now becoming clear that they play a crucial role in
intercellular communication53,54 that may include fusion with their
target cells55. Therefore it is conceivable that DPPE-enriched nano-
particles would behave in a similar fashion as these cellular vesicles in
order to translocate into intracellular compartments of DCs.
Two clear differences between POPE andDPPE that could explain
the differences in cellular uptake are: (i) the presence of an unsat-
urated bond in POPE and (ii) their dissimilar phase transition tem-
peratures from fluid to liquid crystalline of 125uC for POPE35 and
164uC for DPPE36. These distinct differences between 2 otherwise
very similar PEs might determine differences in the fluidity of their
assemblies and rigidity of their bilayers, thereby conveying differ-
ences in the stability of the particulate structures. The character of the
acyl chains in aminophospholipids such as PEs has indeed been
shown to be crucial for the fluidity of a monolayer; saturated chains
lead to lesser membrane fluidity than unsaturated ones56. It was
recently proposed that aminophospholipids with unsaturated oleoyl
chains such as POPE are more prominent in areas of protrusion due
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to their overall conical shape and aminophospholipids consisting of
solely saturated palmitoyl chains (that are considered less conical/
more cylindrical in shape) do not participate in curvature forma-
tion57. Curvature stress is indeed antagonized by addition of more
cylindrical lipids58. Changes in the fluidity of biologicalmembranes is
also attributed to changes inmembrane-initiated signaling processes;
for instance, alcohol potentiation of calcium-activated potassium
channels is favored by cylindrical phospholipids and blunted by
conical ones, regardless of phospholipid head group charge59.
Differences in membrane fluidity for DPPE and POPE nanoparticles
might influence their interaction with DCs and perhaps the mech-
anism of entry into the cells. In future, it will be interesting to study
the mode of internalization for different rigid and fluidic nano-
structures by performing inhibition studies of specific uptake routes
(e.g. energy-dependent processes, clathrin-mediated endocytosis,
caveolae-mediated endocytosis, macropinocytosis)60 and to follow
nanoparticle uptake over time using time-lapse video microscopy61.
State-of-the-art technologies such as computational modeling62 or
four-dimensional electron microscopy63 will shed light in the future
on structure–property relationships of nanocomposites and single-
nanoparticle structural dynamics.
In the present study we showed that the incorporation of DPPE in
19F nanoparticles for labeling of DCs increases the intracellular 19F
signal in DCs by at least one order of magnitude compared to 19F
nanoparticles devoid of DPPE. The observation of an increased
uptake of 19F nanoparticles was demonstrated by 19F MR spectro-
scopy as well as electron and laser scanning microscopy. The micro-
scopy studies demonstrated that nanoparticles are located inside
discrete cytosolic endosomes after internalization by DCs, excluding
the possibility of cell surface attachment. The agarose spot chemo-
taxis assay showed that DCs were less capable at moving towards a
chemokine concentration when increasing 19F label concentration.
Although the migration capability of DCs labeled with DPPE-
enriched fluorine nanoparticles is diminished when compared to
non-enriched nanoparticles, when given at the same PFCE labeling
concentration, lower concentrations of DPPE-enriched fluorine
nanoparticles still resulted in a higher 19F signal per million cells
and minimal decrease in migration, implying a possible threshold
for aminophospholipid enriched nanoparticle labelling concentra-
tion that increases the 19FMRS signal without influencing DCmigra-
tion ability. The order of magnitude increase in 19F signal we
observed with 19F spectroscopy could be translated into two advan-
tages: (i) we could decrease the concentration of the 19F label (PFCE)
from 20 mmol (employed in our original studies5,6,12) to 5 mmol per
107 DCs and thus decrease the impact of the 19F label on cell migra-
tion and (ii) the sensitivity gain considerably improved the cell detec-
tion limit to enable imaging and quantification of DCswithin specific
anatomical regions in vivo.
In conclusion, we present evidence that an enrichment of 19F
nanoparticles with DPPE aminophospholipids enhances their
uptake by DCs, thereby promoting cellular detection by various 19F
MRI and MRS methods. By promoting cellular uptake of 19F label in
cellular transplants — such as in DC vaccines for cancer therapy —
we contribute to some of the solutions required to overcome the
limitations and challenges of cellular MR imaging, particularly with
respect to the barriers pertaining to detection limit and signal
sensitivity.
Methods
Nanoparticle preparation. Nanoparticles with high fluorine content were prepared
by emulsifying Perfluoro-15-crown-5-ether (PFCE, Fluorochem, Derbyshire, UK)
via direct sonication, using a ultrasonic homogenizer (Hielscher Ultrasonic GmbH,
Teltow, Berlin, Germany). PFCE was emulsified in Pluronic F-68 (Sigma-Aldrich,
Germany) for 10 minutes on ice (1.2 M end concentration) to generate a basic
formulation: Basic 19F nanoparticles (NP). To enrich the basic particles with DPPE
(1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, Figure 1A, Avanti Polar Lipid,
Inc., Alabaster, AL) diluted Pluronic-basic nanoparticles were mixed with DPPE and
further emulsified using the same conditions to obtain a final PFCE concentration of
400 mM and varying DPPE concentrations of 2.5–25 mM (DPPE 19F NP). The same
procedure was used to prepare the Pluronic-Rhodamine-DPPE (DPPE-Rhodamine
19F NP) and nanoparticles enriched with POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine, Figure 1A, Avanti Polar Lipid, Inc., Alabaster, AL). DSPE-
PEG2000—PFCE nanoparticles were prepared by first coating a vial with 10 mg of
DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N[methoxy(polyethylene glycol) -2000]), Avanti Polar Lipid, Inc., Alabaster, AL) and
then sonicating PFCE in the vial for 10 minutes on ice, to achieve a final
concentration of 120 mM PFCE and 3.75 mM DSPE-PEG2000.
Zeta potential and other physical characteristics of nanoparticles. To study the
physical characteristics of the above nanoparticles, dynamic light scattering (DLS)
data was obtained using a Zetasizer Nano ZS instrument (Malvern Instruments,
Worcestershire, UK), backscatter detection at 173 degrees and 635 nm laser module
at 25uC. DLS provides information on a number of parameters including intensity-
weighted z-average diameter, peak diameter and width, zeta (f) potential and
polydispersity index (PdI). All these physical characteristics of the different
nanoparticles were documented and are shown in Table 1. The z-average diameter
was used for particle size since it gives an intensity-weighted harmonic diameter and
is ideal for comparing different analyses. The PdI is extrapolated from the DLS
function and quantitatively describes the particle size distribution best. PdI ranges
from 0.01 for monodispersed particles to 0.7 for particles that have a very broad size
distribution. The generated nanoparticles have a PdI, 0.3, indicating a relatively low
polydispersity and narrow size distribution. The f potential was also indirectly
determined by measuring the electrophoretic mobility of the nanoparticles under a
constant voltage of 40 mV at 25uC.
Cryotransmission ElectronMicroscopy (Cryo-TEM) of Nanoparticles.Nanoparticle
preparations were plunge-frozen onto glow discharged holey carbon grids (Quantifoil
Micro Tools, Jena, Germany) in liquid ethane using the environment-controlled
Vitrobot (Vitrobot MarkIV, FEI, Eindhoven, The Netherlands). Briefly, 3 ml of the
nanoparticle solution were applied onto the grid which was held by tweezers inside the
climate chamber (22uC, 100% relative humidity) of the Vitrobot. The solution was
automatically blotted with filter paper leaving a thin film of the nanoparticle solution
over the holes. The film was allowed to relax for 10 s prior to plunge freezing the
sample on the grid in liquid ethane cooled near to its freezing point. Vitrified
nanoparticle samples were imaged at 2170uC using a Gatan cryo-transfer holder
(Gatan 626, Gatan Inc. Pleasanton, USA) and standard low-dose imaging conditions
(1 e2/A˚2.s)64 at a Tecnai G2 F20 transmission electron microscope (FEI, Oregon,
USA), operated at 200 kV. Images were acquired at3 25,000 magnification on a 2k3
2k CCD camera (894 Ultrascan 1000, Gatan Inc., Pleasanton, USA).
DC Preparation. DCs were prepared from bone marrow (BM) suspensions as
previously described65. Briefly, BM from femurs of C57BL/6 mice were grown in
RPMI-1640 medium containing 10% FCS (Biochrom, Germany) and supplemented
with 30 ng/ml GM-CSF. After 9 days in culture, DCs were incubated overnight in the
presence of different 19F nanoparticle preparations (end PFCE concentration ranging
from 0.1–2 mM or 2–40 mmol/106 cells depending on the experiment) and 1 mg/ml
full-length chicken EndoGrade ovalbumin (endotoxin conc.,1 EU/mg; Hyglos,
Regensburg, Germany) and 0.5 mg/ml lipopolysaccharide (LPS). Following
incubation, unbound 19F nanoparticles were washed thoroughly from the culture
dishes by washing with warm PBS. DCs were then harvested and prepared for the
ensuing experiments.
Transmission Electron Microscopy (TEM) of DCs. DCs were fixed for 24 hours in
PBS containing 2% glutaraldehyde and postfixed for 2 h with 1% osmium tetroxide.
Cell pellets were then dehydrated in an ascending series of ethanol and embedded in
Poly/Bed 812 (Polysciences, Eppelheim, Germany). Ultrathin sections were stained
with uranyl acetate and lead citrate. Sections were imaged using a FEI Morgagni
electron microscope (FEI, Eindhoven, The Netherlands) and iTEM software5.
Laser ScanningMicroscopy (LSM) ofDCs. Intracellular fluorescence in DCs labeled
with fluorescently-labeled nanoparticles was investigated using an LSM780 laser
scanning microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany). DCs were
harvested on day 9, washed and seeded onto 4-chamber m-slide plates (Ibidi GmbH,
Mu¨nchen, Germany) and after 4 h labeled with 19F nanoparticles. Prior to LSM,
unbound nanoparticles were washed thoroughly from the m-slide plates by washing
with warm culture medium.
Chemotaxis of DCs. DC motility towards chemokine following labeling with 19F
nanoparticles was determined using an agarose spot assay, as previously described66.
Briefly, a 0.5% agarose solution was prepared, cooled to 40uC and mixed with
chemokine (2000 ng/ml CCL21) or PBS (as –ve control); thereafter the agarose
solution was pipetted as 10 ml spots onto 35-mm glass dishes (MatTek Corporation,
Ashland, MA, USA). Following harvesting, DCs labeled with 19F nanoparticles were
introduced, together with culturemedium, to the glass dishes and incubated for 4 h at
37uC (5% CO2). The number of cells entering the agarose spot was determined by
acquiring and fusing the microscope images for all the fields of views (FOV) making
up the 10 ml agarose spot and counting all cells entering the corresponding spot.
Image processing (including FOV fusion) and analysis (mainly cell counting) were
done with Fiji (Image JA v1.47p, Open source software, NIH, Bethesda, Maryland,
USA)67. For fusing all images the Stitching plugin was used and for counting the
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number of cells within the spot a semi-automatic procedure using the 3D Objects
Counter analyze tool was used.
In vitro 19F MR Spectroscopy (MRS). Following harvesting, DCs (106) labeled with
19F nanoparticles were fixed in 2% PFA and transferred to NMR tubes (external
diameter: 4.947 6 0.019 mm;Wall thickness: 0.043 6 0.02 mm; VWR International
GmbH, Darmstadt, Germany) and the uptake of 19F nanoparticles monitored by 19F
spectroscopy. For this we employed an in-house built 19F-tuned loop RF coil5 for
signal transmission and reception on a 9.4 T animal MRI scanner (Biospec 94/20
USR, Bruker Biospin, Ettlingen, Germany). A 90u block pulse with 10 kHz bandwidth
was used for 19F signal excitation. Spectral representation was done by performing a
fast Fourier transformation (FFT) of the acquired free induction decay (FID). The
amount of PFCE in each sample was calculated from the amplitude of the
extrapolatedmonoexponential decay, at t5 0 of the FID, which is proportional to the
19F concentration. A standard consisting of 500 mM PFCE was used as quantitative
reference in all of these experiments. To determine the cell detection limit of 19F
labeling, voxel-based 19F spectroscopy was performed in phantom experiments using
increasing numbers of 19F-labeled DCs. Fixed cells were suspended in 2% agarose and
transferred to NMR tubes. An NMR tube holder made of acrylonitrile butadiene
styrene (ABS) material was printed in-house using a 3D rapid prototyping system
(BST 1200es, Dimension Inc., Eden Prairie, MN, USA) and customized to fit within a
1H/ 19F dual-tunable volume RF coil (35 mm inner diameter, 50 mm length; Rapid
Biomed, Wu¨rzburg, Germany). For quantification of the 19F content within the fixed
cells in the NMR tubes, we employed Point REsolved SpectroScopy (PRESS) single
voxel spectroscopy. For this purpose we placed a (5 3 5 3 5) mm3 voxel within the
region of interest covering the whole cells in agarose (Figure 6). Then we employed
the FastMap68 method for volume specific magnetic field (B0) shimming. After B0
shimming, the spectra were acquired using a PRESS-protocol for 19F MRS: TR 5
1500 ms, TE 5 11.6 ms, voxel size (5 3 5 3 5) mm3, number of repetitions 5 512,
scan time 5 13 min.
In vitro 19F and 1HMRI of Dendritic Cells. To image the fluorine content within the
NMR tubes holding the fixed cells labeled with 19F nanoparticle we performed 3D
balanced steady state free precession (bSSFP) MRI on the 9.4 T animal MRI using a
custom made 1H/19F dual-tunable volume birdcage resonator (Rapid Biomed,
Wu¨rzburg, Germany) with 35 mm inner diameter and 50 mm length. The bSSFP
sequence was chosen because it was also used for the in vivo experiments (described
below); it has been shown previously to provide very high SNR, allowing for high
spatiotemporal resolution image acquisitions in reasonable scan times, and because it
produces very good soft tissue contrast, related to their T2/T1 relaxation times69. The
scan parameters for bSSFP were as follows for proton (1H) scans: TR 5 6.7 ms, TE 5
3.3 ms, flip angle 5 30u, matrix 5 2563 1283 128, field of view (FOV) 5 (5.83 2.9
3 5.8) cm3, (227 3 227 3 453) mm3 spatial resolution, number of excitations (NEX)
5 1, scan time5 63 sec. For fluorine (19F) scans the parameters for bSSFPwere: TR5
3.6 ms, TE 5 1.8 ms, flip angle 5 30u, matrix 5 64 3 32 3 32, FOV 5 (5.8 3 2.9 3
5.8) cm3, (906 3 906 3 1813) mm3 spatial resolution, NEX 5 64, scan time 5
16.85 min. To reduce banding artefacts across the SSFP images for both nuclei, 4
acquisitions were made using a 0u, 90u, 180u and 270u phase cycling scheme. The four
acquisitions were combined by the sum of squares method using ImageJ (National
Institutes of Health, USA, http://imagej.nih.gov/ij).
In vivo 19F 1H MRI and 19F MRS. Animal experiments were carried out in accordance
with the guidelines provided and approved by the Animal Welfare Department of the
LAGeSo State Office of Health and Social Affairs Berlin (Permit G0070/09:Migration v.
Immunzelltherapien). Following harvesting, 19F-labeled DCs were thoroughly washed
in serum-free buffer and administered intradermally (5 3 106) into the hind limb of
C57BL/6 mice and imaged between 4–18 h following injection. Shortly before and
during the MR session, mice were anesthetized using a mixture of isoflurane as
inhalation narcosis (0.5–1.5%), pressurized air and oxygen. Mice were imaged on the
9.4 T animal MRI using the same 1H/19F dual-tunable volume birdcage resonator as
above (Rapid Biomed, Wu¨rzburg, Germany) and the same 3D bSSFP pulse sequences.
The temperature of the mice was regulated at 37uC. The respiration rate and
temperature was monitored by a remote monitoring system (Model 1025, SA
Instruments Inc., NY, USA). For quantification of the 19F content within the lymph
node regions, we employed the PRESS sequence as above after placing a (3 3 3 3
3) mm3 voxel around the lymph nodes. After FastMap for volume selective B0
shimming, 19F spectra within the lymph nodes were acquired using the same PRESS-
protocol for 19F MRS as above.
MRDataCollection andAnalysis. For both in vivo and in vitroMR-measurements a
Redhat RHEL4 system and Paravision v5 (Bruker Biospin, Ettlingen, Germany)
software were used. NMR data processing, analysis and spectral presentation were
performed in the Matlab environment (Matlab version 7.10.0.499, R2010a, The
MathWorks, Inc., Natick, Massachusetts, USA). Differences between groups were
analyzed by the student t-test. A p-value of p, 0.05 was considered to be statistically
significant.
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